Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial
Titel:
Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial
Auteur:
Gu, Weijie Han, Weiqing Luo, Hong Zhou, Fangjian He, Dalin Ma, Lulin Guo, Hongqian Liang, Chaozhao Chong, Tie Jiang, Jun Chen, Zhiwen Wang, Yong Zou, Qing Tian, Ye Xiao, Jun Huang, Jian Zhu, Shaoxing Dong, Qiang Zhang, Xiaoping Li, Hanzhong Yang, Xinfeng Chen, Chunxia Li, Junliang Jin, Chunlei Zhang, Xiaojing Ye, Dingwei